Previously, we reported that B-cell chronic lymphocytic leukemia (CLL) patients contained elevated levels of microvesicles (MVs). However, given the quiescent nature of CLL B-cells and the relative indolence of the disease, the dynamics of MV generation and their unique phenotypes are not clearly defined. In this study, we find that CLL B-cells generate MVs spontaneously and can be further induced by B-cell receptor-ligation. Most interestingly, CLL B-cells predominantly generate CD52 + MVs, but not CD19 + MVs in vitro, suggesting preferential usage of CD52 into leukemic-MVs and that the CLL plasma MV phenotypes corroborate well with the in vitro findings. Importantly, we detected increased accumulation of CD52 + MVs in previously untreated CLL patients with progressive disease. Finally, sequential studies on MVs in pre-and post-therapy CLL patients demonstrate that although the plasma CD52 + MV levels drop significantly after therapy in most and remain at low levels in some patients, a trend of increased accumulation of CD52 + MVs was detected in majority of post-therapy CLL patients (25 of 33). In total, this study emphasizes that dynamic accumulation of CD52 + MVs in plasma can be used to study CLL progression and may be a useful biomarker for patients as they progress and require therapy.
INTRODUCTION
Cancer cells emit a heterogeneous mixture of vesicular, organellelike structures termed 'microvesicles' (MVs) into their surroundings. 1 Vesicle shedding is preceded by the budding of small cytoplasmic protrusions, which then detach by fission of their stalk. Some release of shedding vesicles takes place from resting cells, however, the rate of the process increases dramatically on stimulation. MVs are generated via diverse biological mechanisms including those featured by activated pathways involved in oncogenic transformation, microenvironmental stimulation, cellular activation, stress or even death. 1 Different biological circumstances under which formation of MVs has been observed reflect the diversity of their biogenesis. Thus, cellular activation, transformation, stress or programmed cell death are associated with a varying MV production output and the nature of the vesicular structures. 2 In addition, depending on the cell type, membrane MVs may be rich in cellular lineage markers. 1 Although it is important to recognize the potential heterogeneity of MV populations, the release of MVs into blood and/or urine calls attention to their promise as circulating-biomarkers in the surveillance of disease progression and/or relapse. We identified increased levels of MVs consisting predominantly of platelet/megakaryocyte-derived MVs 3 in early stage chronic lymphocytic leukemia (CLL) (Rai 0-1) and observed a phenotypic shift of predominantly platelet/megakaryocyte-derived MVs towards more leukemic B-cell-derived MVs in the more advanced Rai stages. 3 In the same study we documented that CLL MVs are able to integrate and activate the CLL bone marrow stromal cells with a dramatically increased level of vascular endothelial growth factor (VEGF), an important survival factor for CLL B-cells. [3] [4] [5] At present, we remain focused in defining the mechanism and dynamics of MV generation and how they may relate to disease progression in CLL.
B-cell receptor (BCR) signaling has a critical role in the behavior of CLL B-cells. CLL B-cells can be subdivided into two major subsets based on the level of hypermutation for the tumor immunoglobulin variable heavy chain (IGVH) genes. 6 Currently, it is believed that CLL B-cells with unmutated IGVH (UM-CLL) status derive from naive CD5 + CD27 − B-cells, whereas CLL B-cells with mutated IGVH genes (M-CLL) status may derive from post germinal center CD5 + CD27 + cells. 7, 8 Importantly, these subsets have distinct clinical behavior where UM-CLL has a more aggressive clinical course. Antigen signaling is thought to be ongoing in both subsets and, rather than the presence or absence of signaling, it is the balance between distinct types of antigen responses in these two subsets that appears to determine clinical behavior. 9 Although, anergy, a state of cellular lethargy that is induced following antigen engagement in the absence of T-cell help, 10 is observed in all CLL B-cells, it is particularly prominent in M-CLL. 9 By contrast, antigen signaling leading to proliferation and survival appears more evident in UM-CLL. A recent report demonstrated that antigen-engagement-induced production of increased levels of exosomes from CLL B-cells, 11 however no report is available on MV generation under similar in vitro experimental conditions. Given the critical role of MVs in modulating CLL tumor microenvironment, 3 we sought to determine the dynamics of MV generation by the leukemic B-cells, and their relevance to the clinical course of CLL.
Our study herein identifies a unique leukemic-derived MV marker, CD52, via both in vitro and in vivo studies. Results from this study also suggest that leukemic B-cell-derived MV plasma levels in CLL are biomarker candidates for changes in the clinical status in CLL. Specifically for the latter, we found that CD52 + MV plasma levels are associated with disease progression/time to therapy and rise in certain patients following therapy.
MATERIALS AND METHODS Reagents
All the chromogen-conjugated antibodies used in flow cytometry and BD Trucount beads were purchased from BD Biosciences (San Jose, CA, USA). Fluorescein isothiocyanate (FITC)-conjugated annexin V was purchased from Life Technologies (Carlsbad, CA, USA). Goat F(ab') 2 anti-human IgM was purchased from SouthernBiotech (Birmingham, AL, USA). Ibrutinib (PCI-32765) was purchased from Selleck Chemical (Houston, TX, USA). 12 Collection of plasma and primary cells All CLL patients provided written informed consent according to the Declaration of Helsinki to the Mayo Clinic Institutional Review Board and the University of Oklahoma Institutional Review Board, which approved these studies. Primary CLL B-cells or normal B-cells were purified from blood samples of previously untreated CLL patients or normal, healthy individuals using the RosetteSep B-cell enrichment kit (StemCell Technologies, Vancouver, BC, Canada) 12, 13 as needed. Cells were cultured in serum-free AIM-V medium (GIBCO, Grand Island, NY, USA). Of note, we did not supplement fetal bovine serum (FBS) to CLL B-cell cultures as prior study found that FBS induces spontaneous apoptosis in CLL B-cells; 14 instead, we used serum-free AIM-V basal media that contain human serum albumin to support primary CLL B-cell growth. Therefore, for comparison and as controls, we cultured purified B-cells isolated from healthy, normal individuals in serum-free AIM-V media, instead of RPMI+10% FBS. 12, 15 Plasma samples were collected from CLL patients or age-matched normal, healthy individuals as described earlier. 3 Plasma samples were also collected from CLL patients (n = 33) who entered onto a clinical trial PCR-B (pentostatin, cyclophosphamide and rituximab (PCR) with bevacizumab (anti-VEGF antibody) 16 conducted at Mayo Clinic at baseline (before therapy) and then sequentially (after therapy) every 6 months until the end of the mandated observation period. In addition, we also collected plasma from treatment naïve CLL patients (n = 9) at the time of diagnosis and a second sample before therapy. Finally, CLL plasma was obtained from a limited number of CLL patients (n = 5) undergoing ibrutinib-therapy at baseline (before initiation of therapy) and after 3 months of therapy. Freshly collected plasmas were made 'platelet-free' as described earlier 3 and kept frozen in aliquots in − 80°C until use.
In vitro BCR-stimulation
Purified CLL B-cells (5.0 × 10 6 /ml) from treatment naïve CLL patients with mutated (n = 15) or unmutated (n = 15) IGVH status were stimulated in vitro with 10 μg/ml goat anti-human IgM for 72 h or left untreated. 17 Purified normal B-cells from healthy individuals (n = 5) were also stimulated for comparison. 'Used' culture media (serum-free AIM-V) were collected by centrifugation to make them cellular debris free and stored in aliquots in − 80°C until use.
Isolation of MVs
MVs were isolated from the plasma samples or used culture media by differential centrifugation as described. 3 Purified MVs resuspended in PBS and stored in − 80°C for subsequent analysis.
Determination of MV levels and phenotypes
Levels and phenotypes of MVs were determined by flow cytometry (BD Canto-I, BD Biosciences) after staining the MVs with annexin V-FITC 3 and chromogen-conjugated antibodies to various relevant cell-surface marker proteins of CLL B-cells and platelet/megakaryocyte. These included antibodies to CD5, CD9, CD19, CD20, CD23, CD37, CD41a, CD52, CD61, PD1, PDL1 and PDL2. BD Trucount beads were used to measure absolute MV levels according to the manufacturer's instructions (BD Biosciences).
Determination of CD19 and CD52 expression levels on normal B-cells and CLL B-cells by flow cytometry
Expression levels of CD19 and CD52 on CLL B-cells and normal B-cells were determined by flow cytometric analysis after staining the cells with chromogen-conjugated isotype control antibodies or antibody to CD19 or CD52. Mean fluorescent intensity (MFI) of the stained cells was used to represent expression levels of each membrane receptor after normalizing with the isotype controls.
Transmission electron microscopy (TEM)
Purified CLL B-cells (5.0 × 10 6 /ml) were cultured in AIM-V medium, collected after 48 h and placed in fixative solution containing 4% formaldehyde and 1% glutaraldehyde in a phosphate buffer, pH 7.3. The fixed sample was manually cut into small pieces and then subjected to a series of chemical solutions that preserved ultrastructure, added stain, removed water and infiltrated with resin. The chemical procedure was as follows: the sample was rinsed with phosphate buffer, followed by treatment with osmium tetroxide, rinsed with water and then treatment with uranyl acetate followed by a water rinse. Sample was then treated with the ethanol series (60-100%; desiccant), 100% acetone (desiccant) and finally, added epoxy resin (Spurr)/acetone mix, then pure resin. The sample was then placed into small plastic 'BEEM' capsules filled with resin and kept in a 60°C oven to polymerize overnight. The sample was sectioned and subjected to TEM.
Purified MVs were stained with uranyl acetate for TEM. A 10 μl MV preparation was allowed to settle on glow discharged copper grids for 3 min. The grids were washed and 10 μl of uranyl acetate, pH 4.4 was added to the grids for 30 s. The grids were washed, air-dried and observed under a Hitachi H7600 Transmission Electron Microscope equipped with a 2 K x 2 K AMT digital camera (Hitachi High-Technologies Corporation, Tokyo, Japan).
Statistical analysis
To compare the MV generation by CLL B-cells between stimulated and unstimulated pathways the Wilcoxon matched-pairs signed-rank test was used. Wilcoxon matched-pairs signed-rank tests were also used to compare levels of CD19 vs CD52 expression on the cell-surface. To compare MV generation between the CLL cohorts (that is, mutated vs unmutated IGVH; normal vs CLL; high vs low Rai-risk; high vs low-risk fluorescence in situ hybridization 9 (FISH)) the Mann-Whitney test was performed. An alpha of 0.05 was used. Graphs were produced using the PRIZM software (GraphPad Software Inc., La Jolla, CA, USA). Statistical tests were performed using SAS version 9.4 software (SAS Institute Inc., Cary, NC, USA).
RESULTS

CLL B-cells generate MVs in vitro
Only a small fraction (varying from 0.1% to 41.0% of the entire clone) of CLL B-cells proliferates in vivo each day, whereas the remainder of CLL B-cells remain largely quiescent. 18 However, CLL is not a static disease rather, it is now known to be a dynamic process composed of leukemic cells that proliferate and undergo apoptosis. 18 Cells when activated or tumor cells, which are highly proliferative and active shed MVs. 19 Thus, here we explored whether the nonproliferative leukemic B-cells from CLL patients (n = 30) shed MVs spontaneously and/or on in vitro BCRstimulation. We detected highly variable levels of spontaneous MV production by the leukemic B-cells after a 72-h culture ( Figure 1a ). However, in vitro stimulation of the BCR signaling pathway significantly increased MV production over spontaneous levels from the leukemic B-cells (P = 0.0005) obtained from majority of the CLL patients (24 of 30; Figure 1a ). Of note, an in vitro time-dependent activation of the BCR signaling in leukemic B-cells detected increased accumulation of MVs after 72 h when compared with 24-or 48-h BCR-stimulation ( Supplementary Figure 1 ). On the basis of published studies, survival, 20,21 rather than apoptosis induction, 22 seems to be the more common response of CLL B-cells to anti-IgM stimulation. 23 Further analysis demonstrated that although both the M-IGVH and UM-IGVH CLL clones produced increased levels of MVs in response to BCR-ligation compared with unstimulated control cells (M-IGVH, P = 0.1688, Figure 1b ; UM-IGVH, P = 0.0002, Figure 1c ), the majority of UM-IGVH clones had a trend to be more sensitive to BCRsimulation than M-IGVH clones. Thus, the median difference of MV levels between stimulated and unstimulated UM-IGVH clones was 14 474 vs 2761 although the difference did not reach statistical significance (P = 0.1688 by the Wilcoxon two-sample test).
CLL B-cells generate predominantly CD52 + MVs in vitro
MVs generated from the purified CLL B-cells in vitro with or without BCR-stimulation described above were phenotyped using antibodies to various cell-surface markers and analyzed on BD Canto-I flow cytometer using standard counting beads. We found that CLL B-cells spontaneously shed primarily CD52 + MVs (P o 0.0001), but not the B-cell lineage specific marker CD19 + MVs (Figure 1d ). However, we also found that the levels of CD52 + MVs were increased (P = 0.0002) but not the CD19 + MV levels (P = 0.7254) on BCR-stimulation of CLL B-cells ( Figure 1d ). Of note, we did not find any significant levels of MVs carrying CD5, CD20, CD23 or CD37 24 markers, nor did we detect MVs simultaneously expressing both CD19 and CD52 proteins (data not shown). Interestingly, we found that normal B-cells also preferentially shed CD52 + MVs (Figure 1e ) under similar in vitro experimental conditions.
Although we found that BCR-ligation augments in vitro MV production, inhibition of the tonic BCR signal in CLL B-cells by ibrutinib 12 did not have any impact on spontaneous production of MVs by the leukemic B-cells in vitro ( Figure 1f ); suggesting that other yet to be defined intrinsic mechanisms in the leukemic B-cells are involved in regulating spontaneous MV production. Given the in vitro findings, we then examined the status of plasma CD52 + MV levels in CLL patients before and after ibrutinib-therapy. To begin to do this, we collected plasma MVs from CLL patients (n = 5) before and 3 months after ibrutinibtherapy and determined CD52 + MV levels. We found that 4 of 5 CLL patients exhibited reduced levels of plasma CD52 + MVs after 3 months of therapy as compared with the pre-therapy CLL plasma samples (Figure 1g ). It is possible that the reduction of CD52 + MV levels after 3 months of ibrutinib-treatment resulted from reduced tumor burden in the CLL patients. To support this possibility we found that the Pearson correlation measurement between the changes in CD52 + MV levels and absolute lymphocyte counts (ALC) was 0.98 (95% confidence interval 0.76-1) suggesting a positive association between the two parameters in this small cohort.
To further validate that CLL B-cells are able to shed MVs spontaneously, we performed TEM of purified CLL B-cells with UM-IGVH cultured in vitro for 48 h without exogenous stimulation. Observation of the cells under electron microscope suggests that indeed CLL B-cells shed MVs (Figures 2a-c ). In addition, it would appear based on size determination that both exosomes and MVs are being produced by CLL B-cells. Similarly, we were also able to detect MVs purified from 'used' media (72 h) of in vitro CLL B-cell culture (Figure 2d ) as well as CLL plasma (Figure 2e ) obtained from the same CLL patient as heterogeneous populations under EM as reported earlier. 3 
CLL B-cells and normal B-cells express higher levels of CD52 than CD19
Given that we had found CLL B-cells shed primarily CD52 + MVs but not CD19 + MVs, we then wished to determine the comparative expression levels of CD19 and CD52 on normal and leukemic B-cells. For this, both cell types were stained with an antibody to CD19 or CD52 and analyzed by flow cytometry. Our findings suggest that both normal B-and CLL B-cells express significantly higher levels of CD52 than CD19 (P o 0.0001) ( Figure 2f ). Interestingly, the mean expression level of CD52 on normal B-cells was~threefold higher than that on the leukemic B-cells (Po 0.0001). Given this latter data, we hypothesized that lower expression levels of CD52 on CLL B-cells could be a result of increased shedding of CD52 + MVs by the leukemic cells.
Shedding of CD52 + MVs results in reduction of CD52 expression levels on CLL B-cells To address the above hypothesis, we next investigated whether shedding of CD52 + MVs in vitro either spontaneously or on BCRstimulation reduced expression levels of CD52 on CLL B-cells. For this, expression levels of CD52 and CD19 on freshly isolated, purified CLL B-cells were determined by flow cytometric analyses immediately before culture (time 0) or after 72 h of in vitro culture with or without BCR-stimulation. Interestingly, we found that although there was no detectable alteration of the CD19 membrane expression levels on CLL B-cells, significant reduction of CD52 levels on CLL B-cells was discernible after 72 h of in vitro culture with (P o0.0001) or without (P = 0.006) BCR-stimulation ( Figure 2g ). This finding is consistent with the possibility that shedding of CD52 + MVs is, at least in part, responsible for the lower levels of CD52 on CLL B-cells. To this end, we examined if there is an inverse association between shedding of CD52 + MVs by CLL B-cells and their cell-surface CD52 expression levels. For this, purified CLL B-cells from previously untreated CLL patients (n = 11) were stimulated by BCR-ligation or left unstimulated in vitro for 72 h. Levels of CD52 + MVs in the used culture media and CD52 expression levels on CLL B-cells with or without BCR-stimulation were then determined. Consistent with our observation above ( Figure 2g ) we found a decrease of CD52 membrane levels on CLL B-cells following BCR-stimulation when compared with the unstimulated control cells (Figure 2h ). The median decrease of membrane CD52 expression assessed by change in CD52 MFI on CLL B-cells after BCR-stimulation was − 75 (MFI ranged from − 498.2 to − 2). In contrast, increased shedding of CD52 + MVs, albeit at variable levels (median increase was 7291 with a range from 282 to 103 768), by the leukemic B-cells was noted after in vitro BCR engagement. Although the difference was variable and not normally distributed, a Spearman correlation analysis between these differences found a Spearman rho of − 0.60 (a P-value of 0.0510) indicating an inverse relationship between (f) Inhibition of BCR signal pathway showed no impact on spontaneous generation of MVs. Freshly isolated, purified CLL B-cells from previously untreated CLL patients (n = 5) with UM-IGVH status were treated with 0.5 μM of ibrutinib and cultured for 72 h or left untreated. MVs were isolated from the used culture media and total MV levels were determined as described above. Values of individual CLL patients are shown. (g) Ibrutinib-therapy reduced CD52 + MV levels in CLL circulation. MVs were isolated from plasma of CLL patients (n = 5) before (baseline) and 3 months after ibrutinib-therapy. MVs were phenotyped and levels of CD52 + MVs in CLL plasma were determined as described above. Values of individual CLL patients are shown. Four of five CLL patients showed substantial reduction of plasma CD52 + MV levels 3 months after ibrutinib-therapy.
the CD52 expression on CLL B-cell-surface and the CD52 + MV shedding by CLL B-cells.
Shedding of CD52 + MVs is a property of human B-lymphocytes
Having detected predominantly CD52 + MVs in the culture media of purified CLL B-cells or normal B-cells, we investigated whether CLL plasma or normal plasma from healthy individuals had primarily CD52 + MVs vs CD19 + MVs. To address this, MVs were isolated from CLL (n = 33) or normal (n = 10) plasma and phenotyped. Indeed we detected significantly higher levels (P o 0.0001) of CD52 + MVs as compared with CD19 + MVs in CLL circulation (Figure 3a ). MVs isolated from plasma of normal, healthy individuals also showed similar patterns of MV phenotypes (CD19 + vs CD52 + MV levels had a median difference of 15 896; P = 0.002) albeit at significantly lower levels than those in CLL plasma. When we compared differences between CD52 + and CD19 + MV levels for normal and CLL plasma samples, we found a P-value of 0.0002 comparing the median values in both; normal plasma = 15 896, CLL plasma = 115 624 ( Figure 3a) . Thus, the phenotype pattern of plasma MVs in CLL patients is similar to the phenotypes of in vitro generated MVs from leukemic B-cells.
Next, we explored whether the levels of CD52 + MVs in CLL plasma were associated with known prognostic CLL risk factors. To that end, further analysis of the CLL plasma MV phenotypes (as shown in Figure 3a ) detected no significant difference in the levels of CD19 + (P = 0.4824) or CD52 + (P = 0.6525) MVs between the CLL patients with M-IGVH vs UM-IGVH status (Figure 3b ). Although the levels of CD52 + MVs in CLL circulation did not show any positive association to high Rai-risk (Rai-III/IV) vs low Rai-risk (Rai 0/I) CLL patients (Figure 3c ; median 145 511 vs 138 317, P = 0.9661), we did detect a trend for CD52 + MV levels to increase in CLL patients with high-risk FISH (17p-/11q-) when compared with CLL cohort with low-risk FISH (13q-/Tri12 or no genetic abnormalities) (Figure 3d ; median 166 186 vs 94 402, P = 0.1635).
Accumulation of CD52 + MVs may predict CLL progression or time of therapy
We next attempted to determine whether leukemic B-cell-derived MV levels in CLL patients were associated with disease progression and time to therapy. Initially, we isolated MVs from the plasma of a small CLL patient cohort (n = 9) at or near diagnosis and at time points close (0.4-1.8 months) to initiation of therapy (n = 6) or 2-8 months before start of therapy (n = 3). We found that CD52 + MV levels in CLL plasma increased substantially a few weeks before clinical detection of disease progression (Figure 4) . In most cases, the progression event was accompanied by an increase in Rai-stage, ALC values and/or a decrease in platelet counts (Figure 4 ; Supplementary Table 1 ) however, all patients were subsequently treated. It was also found that increase of plasma CD52 + MV levels was associated with increases of ALC levels (7 of 9 patients) and/or progression to higher Rai stages (6 of 9 patients). Interestingly, platelet-derived (CD61 + ) MV levels were also increased despite moderate to severe thrombocytopenia (Figure 4 ). Of note, MV parameters in plasma from two CLL patients with stable disease did not show a significant increase of leukemic B-cell derived MVs in their circulation over a period of 9-12 months ( Supplementary Figure 2 ). Together these observations suggest that accumulation of CD52 + MVs in CLL may be associated with disease progression in previously untreated patients.
Dynamics of leukemic B-cell-derived MVs in pre-and post-therapy CLL patients
To further define the dynamics of MV levels in CLL, we assessed sequentially the plasma levels of MV generation in CLL patients who were treated. Here, MVs were isolated from plasma of CLL patients (n = 33) who were treated with six cycles of a PCR-B therapeutic regimen previously reported 16 at baseline (just before therapy) and then every 6 months for a maximum of 4 years after therapy. Leukemic B-cell-derived MV (CD52 + ) levels were plotted against the blood ALC values and shown graphically in Figure 5 and in Supplementary Figures 3A-C . CD52 + MV levels dropped after therapy within 6-12 months in most (27 of 33) of the CLL patients, although in 6 of 33 (18%) CLL patients (P16, P17, P19, P20, P22, P25), we observed an initial rise of CD52 + MV levels after therapy, which was then followed by a decrease in MV levels ( Figure 5 ; Supplementary Figures 3A and B) . In addition, we noted rising levels of plasma CD52 + MVs in post-therapy CLL plasma after an initial drop with no obvious disease progression (16 of 33) ( Figure 5 ; Supplementary Figures 3A-C) . Of importance, 7 of these 16 patients progressed at later time points with a median relapse time of 45 months from the time of therapy.
DISCUSSION
In this study we evaluated the in vitro dynamics of MV generation by CLL leukemic B-cells known to be largely quiescent. 18 Comparison between the CD19 and CD52 expression levels on cell-surface within each group or between the two groups was analyzed and presented. (g) Increased shedding of CD52 + MVs is associated with reduced CD52 levels on CLL B-cells. CLL B-cells were stained with a chromogen-conjugated antibody to CD52 or CD19 before in vitro culture (time 0) or after a 72-h culture with or without anti-IgM treatment. Expression levels of CD19 or CD52 were determined by flow cytometric analysis and presented as MFI after normalizing with the isotype controls. Mean MFI values with standard deviations are shown. (h) Association of increased CD52 + MV levels in culture and simultaneous reduction of CD52 expression levels on CLL B-cells. Freshly isolated, purified CLL B-cells from previously untreated CLL patients (n = 11) were stimulated in vitro with anti-IgM treatment or left unstimulated for 72 h in culture. Cells were collected, stained with a chromogen-conjugated antibody to CD52 and analyzed by flow cytometry to determine CD52 expression levels. MVs were isolated from the used culture media and the CD52 + MV levels in culture were determined by flow cytometric analysis as described elsewhere. Difference of CD52 expression levels (MFI) on CLL B-cells and levels of CD52 + MV levels shed by the leukemic B-cells before and after BCR-stimulation was determined, and we performed a Spearman correlation between these differences. The Spearman rho is − 0.60 with a P-value of 0.0510 indicating an inverse relationship between the CD52 + MV levels found in culture medium when compared with the expression levels of CD52 on CLL B-cells.
We found that although in vitro BCR-stimulation significantly increased MV production from CLL B-cells with UM-IGVH status, leukemic B-cells with M-IGVH status also responded well to BCRligation based on in vitro MV production. There was a subset of CLL clones with M-IGVH status where we found a decrease in the in vitro MV production on BCR-stimulation. It is unclear why this occurred but may be a result of cellular anergy in CLL B-cells on antigen engagement in the absence of T-cell help that is more prominent in M-CLL. 9 Of interest, further analysis suggests that the tonic BCR signal may not be the only factor influencing spontaneous shedding of MVs by the leukemic B-cells, as in vitro ibrutinib-treatment could not block basal level production of MVs from CLL B-cells, whereas it is known that ibrutinib can block exosome production. 11 Given this, it is likely that other intrinsic and/or tumor microenvironmental factors yet to be elucidated are critically involved in regulating the spontaneous generation of MVs from CLL B-cells. However, the reduction of plasma CD52 + MVs by ibrutinib reinforces the possibility that MV plasma levels can be biomarkers for CLL disease status. This work also detected significantly higher levels of CD52 + MVs compared with CD19 + MVs in our in vitro CLL B-cell culture system. In many cases secreted MVs carry surface receptors characteristic of the originator cells. 25 Of note, although we detected a lower level of in vitro generated MVs carrying CD19 antigen, there were also remarkably low or undetectable levels of CD5 + , CD23 + or CD37 + MVs in the in vitro generated MV pool. We also found that CLL B-cells and normal B-cells both express significantly higher levels of CD52 than CD19 on cell-surface; however, normal B-cells express~threefold higher CD52 levels compared with that on leukemic B-cells. Given this, we hypothesized that increased shedding of CD52 + MVs by the leukemic B-cells is a process that might result in the reduced expression of CD52 on the cell-surface. Indeed, we detected significant reduction of CD52 levels on CLL B-cell-surface after 72 h of culture, whereas no significant alteration of the CD19 levels under similar experimental conditions was observed. Thus, it appears that spontaneous or induced production of CD52 + MVs can contribute to a reduction of CD52 expression levels on CLL B-cells. As further confirmation of the latter possibility, we detected an inverse correlation between decrease of CD52 expression levels on CLL B-cells and increased shedding of CD52 + MVs by the leukemic B-cells after BCRstimulation. Of importance, in vivo findings on MV phenotypes isolated from CLL plasma also corroborate well with the in vitro observation that CLL B-cells primarily generate CD52 + MVs. Further analysis suggests that normal B-cells also generate primarily CD52 + MVs in vitro and in vivo albeit at much lower levels than the leukemic B-cells suggesting that the generation and shedding of CD52 + MVs is a physiologic characteristic of human B-lymphocytes. To our knowledge, this is the first report to demonstrate that CLL B-cells/normal B-cells tend to shed predominantly CD52 + MVs, not CD19 + MVs.
In explaining why CD52, but not CD19, is preferentially a component of leukemic-MVs it is important to take into context the known function of each. CD52 is a small, heavily glycosylated protein of 12 amino acids anchored to glycosylphosphatidylinositol and expressed at high levels (5x10 5 molecules per cell) on human lymphocytes, sperm cells and monocytes. 26, 27 CD52 is also a very effective target for CD52 specific monoclonal antibodies (that is, alemtuzumab) in the induction of complement mediated lysis, antibody-mediated cellular cytotoxicity, 28 and results in very dramatic depletion of T-and B-cells in vivo. 29 Thus, leukemic B-cells may escape complement mediated lysis and/or cytotoxic effects of the antibody-based therapeutic agent, alemtuzumab, by shedding increased levels of CD52 + MVs in circulation. It is reported in earlier studies that CLL plasma contain increased levels of free-circulating soluble CD52; 30 however, given our current work we believe CD52 is bound to plasma MVs. 3 As CD52 is highly negatively charged and present on sperm cells and lymphocytes, it has been conjectured that its function is related to anti-adhesion activity, allowing cells to freely circulate. 31 Of note, CD52 binds the ITIM (Immunoreceptor tyrosine-based inhibitory motif)-bearing sialic acid-binding lectin SIGLEC10. 32 In contrast, CD19 is critically involved in establishing intrinsic B-cell-signaling thresholds through modulating both BCR-dependent and independent signaling. 33, 34 CD19 acts as a vital co-receptor for BCR signal transduction, and recruits and amplifies the activation of Srcfamily protein tyrosine kinases such as Lyn and Fyn. [35] [36] [37] [38] On BCR activation, CD19 also enhances BCR-induced signaling crucial for B-cell expansion, through recruitment and activation of PI3K and downstream Akt kinases. 39 It also functions as the dominant signaling component of a multimolecular complex on the surface of mature B-cells, alongside complement receptor CD21 (CD2), and the tetraspanin membrane protein CD81 (TAPA-1), as well as CD225. 35, 36, 40, 41 CD19 is critical for B-cell signaling and expansion, whereas the role of CD52 in B-cell survival is not yet well defined, but given the above we would propose that it is likely that CLL B-cells or normal B-cells need to preferentially retain CD19 as it is a key factor involved in B-cell-survival signaling complex.
Having established that CLL B-cells preferentially shed CD52 + MVs both in vitro and in vivo, we interrogated whether increasing plasma accumulation of leukemic B-cell-derived MVs would be predictive of disease progression. Indeed in CLL patients (n = 9) with evidence for progression, we detected an increase of CD52 + MVs in circulation of 7 of 9 CLL patients as they progressed from a more indolent phase, although no significant alteration of the CD52 + MV levels was found in two CLL patients with stable disease. These early findings, although seen in only a small cohort of CLL patients, do indicate that further validation in a much larger cohort will be of value in continuing to pursue the possibility that CD52 + MVs can be a biomarker of disease status in CLL.
To further our knowledge of in vivo MV dynamics in CLL patients, we studied MV parameters in pre-and post-therapy CLL plasma in a cohort of 33 CLL patients treated with the PCR-B protocol. Although plasma CD52 + MV levels dropped in the majority of CLL patients 6-12 months after therapy, in~48% cases, CD52 + MV levels started to rise with time with no apparent sign of clinical progression. The observed rise of post-therapy plasma CD52 + MV levels appears to be independent of the status of the clinical response of the patients to therapy as determined at 6 months of treatment, for example, complete remission (CR), partial remission (PR) or nodular(n)PR ( Figure 5 ; Supplementary  Figures 3A-C) . Two relevant observations in the PCR-B patient study were: (i) elevation of CD52 + MV levels in post-therapy CLL plasma at early time points with clinical manifestation of the disease only noted at a later time point (n = 10) and subsequent treatment; and (ii) elevation of CD52 + MV levels in post-therapy CLL plasma (n = 16) where there were no signs of clinical progression over the time of observation ( Figure 5 ; Supplementary Figures 3A-C) . Although intermittent elevations of CD52 + MV levels can be a result of leukemic B-cell activation in patients who have infections or inflammatory complications, a steady and consistent rise of CD52 + MV levels in the latter scenario is most likely an early indication of leukemic growth and future relapse. We believe that collection of sequential blood samples for MV evaluation at shorter time intervals could be critical in assessing the value of CD52 + MVs as biomarker for CLL disease. As MVs are released from leukemic B-cells regardless of IGVH status and which tissue site they reside in and ultimately circulate into the plasma pool, it is feasible that serial, timely and accurate measurements of plasma MVs will be found to be extremely sensitive biomarker measures of tumor burden and/or progression. Further studies are needed to validate this possibility as it does hold the promise of predicting occurrence of relapse earlier than clinical manifestation of the disease.
In summary, our studies have found that CLL B-cells whether of mutated or unmutated IGVH status can produce and secrete CD52 + MVs. The stimulation of MV generation by BCR-ligation can accentuate the spontaneous production of MVs from CLL B-cells whether of mutated or unmutated status indicating that the microenvironment can modulate MV production in CLL. In addition, the levels of MVs appear to be associated with disease progression for previously untreated CLL. Future studies are now focused on a more extensive analysis of plasma CD52 + MVs in association with CLL disease progression, depth of clinical response, clinical complications such as infections and to determine if the elevation of the CD52 + MV plasma level may be a relevant biomarker predictive of progression or relapse for both previously untreated and treated CLL patients, respectively. experiments; SKV performed statistical analysis of the data; TDS provided clinical samples with relevant information; NEK provided clinical samples with relevant information, analyzed data and edited the manuscript; AKG conceived and supervised the project, designed the research, analyzed data and wrote the manuscript; and all authors read and approved the final manuscript.
